ArticleDevelopmental neuroscience2026
A Pilot Study on Dynamic Multimodal Neuromonitoring for Predicting Neurodevelopmental Outcomes in Neonatal Hypoxic-Ischemic Encephalopathy.
Article in Developmental neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Data-driven wavelet coherence approach to assess neurovascular coupling in neonatal hypoxic-ischemic encephalopathy.Neurophotonics · 2026Article
- Multi-organ involvement in preterm neonatal encephalopathy.Early human development · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionMultimodal neuromonitoring at the bedside is essential for understanding the pathophysiological mechanisms of brain injury and neurodevelopmental outcomes associated with neonatal hypoxic-ischemic encephalopathy (HIE). While previous research has focused on single modality neuromonitoring biomarkers to predict neurodevelopmental impairment (NDI) at 2 years of age, there remains significant gap in exploring the potential of multimodal physiological signal biomarkers to improve predictive accuracy. This study aimed to evaluate multimodal quantitative neuromonitoring biomarkers within the first day of life to improve prediction of NDI.
methodsThis prospective cohort study enrolled newborns (≥36 weeks) diagnosed with HIE at Parkland Hospital in Dallas, TX. A Sarnat examination was performed to determine the severity of HIE within the first 6 h of life, and the Total Sarnat Score (TSS) was calculated. Newborns with moderate and severe HIE received therapeutic hypothermia (TH). Neuronal noninvasive biomarkers including electroencephalogram (EEG) delta power (DP, 0.5-4 Hz) and neurovascular coupling (NVC), calculated as wavelet coherence between amplitude-integrated EEG and cerebral tissue oxygen saturation (SctO
resultsForty-six newborns with mild to severe HIE were enrolled and neuromonitoring was initiated at 12 ± 6 h of life. Death or NDI was diagnosed in 18 (6 mild, 10 moderate, 2 severe) infants. Eight out of 46 infants did not complete the 18-24 months follow-up but had a normal examination prior. The combination of all three biomarkers (TSS, DP, and NVC) yielded the highest AUC of 0.755 (95% CI: 0.569-0.941), with sensitivity of 0.750, specificity of 0.769, positive predictive value of 0.800, and negative predictive value of 0.714, outperforming individual biomarkers or two-marker combinations. Furthermore, the NRI analysis demonstrated that the combined model achieved the highest NRI value (0.5577), indicating the strongest improvement in risk classification.
conclusionThis study emphasizes the importance of implementing multimodal neuromonitoring and integrating quantitative biomarkers at the bedside during the first day of life to provide objective metrics on brain health in addition to neurological exam. These approaches demonstrate potential for enhancing the prediction of encephalopathy severity, brain injury, and NDI in the early hours of life, aiding clinicians in timely and effective decision-making for neuroprotective interventions. However, validation through multicenter studies with large cohorts is needed for clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.